UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000026050 |
|---|---|
| Receipt number | R000029938 |
| Scientific Title | Phase II study to assess efficacy, safety & immunological biomarker of anti PD-L1 antibody + anti CTLA-4 antibody in combination with hormone therapy in patients with hormone receptor positive HER2-negative recurrent or metastatic breast cancer |
| Date of disclosure of the study information | 2017/02/08 |
| Last modified on | 2019/02/07 06:04:51 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/02/08 13:57:47 | ||
| 2 | Update | 2018/03/02 19:26:54 | Anticipated trial start date |
|
| 3 | Update | 2018/04/09 16:04:41 | Division name Division name TEL Organization Organization Division name Division name Address TEL Institute |
|
| 4 | Update | 2018/08/25 14:16:14 | Recruitment status |
|
| 5 | Update | 2018/10/31 06:24:08 | Email Organization Organization Address |
|
| 6 | Update | 2019/02/07 06:04:51 | Email |
